L-Carnitine
L-Carnitine / ALCAR
L-Carnitine (L-Carnitine / ALCAR) is a metabolic & fat loss research compound. Shuttles long-chain fatty acids into mitochondria for oxidation — supports fat metabolism and recovery.
L-Carnitine quick facts
| Reported research dose | 300mg-1000mg |
| Route | Either |
| Frequency | 1-2x Daily Pre Exercise · Daily or On Workout Days |
| Half-life | ~15 hrs (oral) |
| Forms | Injectable |
| Evidence level | Human (supplement) |
Injectable/pre-workout timing is where people feel the fat-oxidation and pump benefit.
How L-Carnitine works
Shuttles long-chain fatty acids into mitochondria for oxidation — supports fat metabolism and recovery.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get L-Carnitine
Buy L-Carnitine at AminoWell USA →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for L-Carnitine
Graded by what exists behind each claim.
✅ Clinically validated
- Randomized human trials exist and the useful finding is not the fat-loss one. Trials of oral carnitine for weight loss show small, inconsistent effects at best in healthy people.
- Where it is clearly effective is deficiency — it is approved for primary and secondary carnitine deficiency, and it has real evidence in dialysis patients and in valproate toxicity.
- Some trials report reduced muscle soreness and improved recovery markers after exercise, which is a more defensible claim than the metabolic one.
📊 Correlative data
- Very wide use. The practical constraint is that oral carnitine barely raises muscle carnitine — muscle uptake is insulin-dependent, which is why the studies that show muscle content changes used carnitine with a large carbohydrate load or intravenous delivery.
- Oral carnitine is metabolized by gut bacteria to TMAO, which has been associated with cardiovascular risk in observational work — contested, unresolved, and worth knowing.
🧪 Theoretical / extrapolated
- Carnitine shuttles long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase system. Without it, fat cannot be oxidized.
- Being required is not the same as being limiting. In someone eating normally, muscle carnitine is already near saturation — which is precisely why supplementation moves little and why the deficiency evidence is strong while the enhancement evidence is not.
- Acetyl-L-carnitine crosses the blood-brain barrier and is a different proposition with a different (cognitive) literature.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What L-Carnitine actually does
Carnitine does exactly one indispensable chemical job, and almost everything sold about it is downstream of a different job nobody mentions. The famous one is the shuttle: a long-chain fatty acid cannot cross the inner mitochondrial membrane as an acyl-CoA, so carnitine palmitoyltransferase 1 on the outer membrane swaps the CoA for carnitine, the acylcarnitine crosses on the carnitine-acylcarnitine translocase, and CPT2 on the inside swaps it back. Without carnitine, long-chain fat cannot be oxidized at all.
The job nobody mentions is the acetyl buffer, and it is probably the one that matters at supplement doses. Carnitine acetyltransferase converts excess mitochondrial acetyl-CoA into acetylcarnitine, which can leave the mitochondrion. That frees up the CoA pool and relieves the acetyl-CoA inhibition of pyruvate dehydrogenase — which is a glucose-handling effect, not a fat-burning one. The human trial that moved insulin sensitivity measured exactly this: 2,970 mg/day for 12 weeks in type 2 diabetes improved insulin-induced glucose suppression from 31.9 ± 2.9% to 39.9 ± 3.2% (p=0.020) and peripheral insulin sensitivity from 10.53 ± 1.85 to 13.83 ± 2.02 micromol/kg/min (p=0.005), with skeletal muscle acetylcarnitine formation as the named mechanism Op den Kamp-Bruls 2025. The carnitine pool does far more than shuttle fat Xiang 2025 Alhasaniah 2023.
And here is the constraint the entire product category ignores: muscle carnitine is 100-fold concentrated against plasma, and getting more in is an active transport problem, not a supply problem. OCTN2 (SLC22A5) is a sodium-coupled symporter — its structure shows the sodium site that powers uphill carnitine transport Davies 2025. Raising plasma carnitine does not push carnitine into muscle any more than raising outside air pressure fills a scuba tank. What moves the transporter is insulin, which increases OCTN2-mediated uptake into skeletal muscle. That is why every human study that successfully raised muscle carnitine fed carbohydrate alongside it, and why a milligram number on a card without a carbohydrate number beside it is describing the wrong variable.
Cell, rodent, human — and where it stops
Step one, the transporter, which is now solved at atomic resolution. The structural basis of sodium-dependent carnitine transport by OCTN2 was published in 2025 Davies 2025; the carnitine pool's roles beyond fat oxidation are reviewed with the biochemistry intact Xiang 2025. Nothing downstream depends on guessing how carnitine gets into a cell.
Step two, in humans, on the fat-oxidation claim — and this is the study the page should be built on. Older individuals given carnitine achieved a 20% increase in muscle total carnitine content and a 20% increase in total fat oxidation during moderate-intensity exercise, with increased expression of fat metabolism genes Chee 2021. Two things about that result matter more than the headline. First, the fat-oxidation gain and the muscle-content gain were the same size, which is what you would expect if muscle content is the rate-limiting variable. Second, in the same study resting insulin-stimulated glucose disposal did not change — so the effect was specific to exercising fat oxidation, not a general metabolic improvement.
Step three, in humans, on the insulin-sensitivity claim. A separate trial at 2,970 mg/day for 12 weeks did move insulin sensitivity in type 2 diabetes Op den Kamp-Bruls 2025. Note the dose. The card here prints 300–1000 mg. The human trials that produced measurable change used roughly three grams a day, for months. That is not a small discrepancy; it is a threefold gap at the top of the card's range and a tenfold gap at the bottom.
The obstacle, named precisely. Raising muscle carnitine requires sustained hyperinsulinemia alongside the dose, and the published protocols achieved it by co-ingesting large amounts of carbohydrate, for weeks to months. In a person eating to lose fat, that co-requirement is either impractical or self-defeating. The conditions that make carnitine work in a trial are close to the opposite of the conditions the person buying it is in. Nobody has solved that, and injecting does not solve it, because the barrier is the muscle membrane and not the gut.
L-Carnitine pharmacokinetics — how much of it actually gets in
The card prints ~15 hours (oral). That number is about plasma. The number that matters is about muscle, and it is measured in weeks.
What clears it. Carnitine is not metabolized by a cytochrome. Its principal fate is renal clearance, and the kidney is unusually good at holding onto it: OCTN2 in the proximal tubule reabsorbs the great majority of the filtered load, so renal clearance rises steeply once plasma exceeds the normal range. That is the mechanism behind the low bioavailability of a large oral dose — you absorb some, plasma rises past the reabsorption threshold, and the kidney throws the excess away. The clearest demonstration of how carnitine kinetics behave when the kidney is removed from the equation comes from dialysis, where supplementation was reduced and carnitine kinetics tracked directly Sugiyama 2021.
The oral barrier, and the second, larger barrier behind it. Oral bioavailability of L-carnitine is low — a minority of a gram-scale dose is absorbed, the rest is fermented by gut bacteria — and absorption is carrier-mediated and therefore saturable, so doubling the dose does not double the absorbed amount. But the real barrier is downstream: even fully absorbed carnitine still has to cross a 100-fold concentration gradient into muscle against sodium-coupled transport Davies 2025.
Numbers, and the one that reframes the product. Muscle content rose 20% in the human study, and the protocols that achieve it run for weeks to months with insulin support Chee 2021; the insulin-sensitivity trial ran 12 weeks at 2,970 mg/day Op den Kamp-Bruls 2025. So the meaningful pharmacokinetic parameter for this compound is not a plasma half-life at all — it is a tissue loading time constant, and it is on the order of a month. A dose taken 30 minutes pre-workout is not changing muscle carnitine that day, by any published kinetics.
The injectable comparator, honestly. Injection removes the gut barrier and raises plasma carnitine far more efficiently than an oral dose. It does not touch the muscle-membrane barrier, and it may make renal loss faster, because a higher plasma peak is further above the tubular reabsorption threshold. The route fixes the smaller of the two obstacles and can worsen the retention. That is the single most important thing an injectable carnitine page can say.
What would have to be true, and how you would know it was not
Three predictions. The third is the one that argues against the product as it is usually taken.
1. TMAO should rise, in omnivores more than in vegetarians, and this is the most reliably predictable change on the page. Gut bacteria convert carnitine to gamma-butyrobetaine and then to trimethylamine by an anaerobic pathway that has now been worked out enzymatically Rajakovich 2021, and hepatic flavin-containing monooxygenase 3 oxidizes that to TMAO, which is associated with atherosclerosis Koeth 2013. Draw TMAO at baseline and at 8 weeks. Prediction: it rises, and the size of the rise depends on the microbiome rather than the dose — which makes this one of the few supplements whose main measurable systemic effect is determined by what you have been eating for years.
2. Fasting insulin should improve only at gram-scale doses and only after months. The trial that moved it used 2,970 mg/day for 12 weeks Op den Kamp-Bruls 2025. Draw fasting insulin and HbA1c at baseline and at 12 weeks, at a documented daily dose. Prediction: nothing at 500 mg, something at 3 g. That is a clean dose-threshold test and it would tell a reader whether the product they own is in the range that has ever worked.
3. The prediction that cuts against it: total and free carnitine will look fine whether or not anything is working. Carnitine, total and free is an orderable serum test, and it measures plasma — the compartment the supplement raises easily and the one that does not determine fat oxidation. Muscle content, which does, requires a biopsy. So the prediction is: serum carnitine rises, and it will not correlate with anything you can feel. A reader who takes a normal or high serum carnitine as evidence the supplement is working has measured the wrong compartment, and that is the commonest error made about this molecule.
What nobody has tested yet
Four experiments that have never been run.
Nobody has measured muscle carnitine after INJECTED carnitine. Every human muscle-loading study used the oral route with insulin support Chee 2021. Whether a subcutaneous or intramuscular dose loads muscle at all — given that the barrier is the sarcolemmal transporter rather than the gut Davies 2025 — is the central unanswered question for the form this Vault page actually sells, and it has never been asked.
Nobody has tested carnitine plus a small insulin stimulus instead of a large carbohydrate load. The loading protocols work by raising insulin. Whether a much smaller carbohydrate dose, or timing around a meal, achieves the same OCTN2 trafficking is a practical question with an obvious design and no published answer.
Nobody has stratified carnitine response by microbiome. The TMA-producing pathway is bacterial and now enzymatically defined Rajakovich 2021. Two people on the same dose can have very different TMAO exposures. Nobody has asked whether the people who get the most benefit are the ones who make the least TMAO — which, if true, would make a stool or TMAO measurement a genuine before-you-start variable.
Nobody has run the acetylcarnitine buffer hypothesis in trained people. The insulin-sensitivity result came from type 2 diabetes Op den Kamp-Bruls 2025; the fat-oxidation result came from older, untrained individuals Chee 2021. Whether a trained person with already-high muscle carnitine and already-good pyruvate dehydrogenase flux has any headroom left is the exact question the buying audience is in, and there is no study of it.
L-Carnitine — its own safety story, not its class's
This compound's own risk story is a gut-microbial metabolite and a kidney, and neither appears in the class block below.
TMAO is the real one, and it is a mechanism rather than a correlation. Intestinal microbial metabolism of L-carnitine produces trimethylamine, which the liver oxidizes to TMAO, and that pathway promoted atherosclerosis in the work that put it on the map Koeth 2013; the intermediate steps have since been resolved down to the bacterial enzymes involved Rajakovich 2021. Whether the association translates into human events at supplement doses is genuinely unsettled — but this is a supplement whose best-documented systemic effect in a healthy person is the production of a metabolite associated with vascular disease, and a page selling it should say so first rather than last.
The kidney is where carnitine handling lives, and impaired kidneys change the whole picture. Carnitine is renally cleared and renally reabsorbed, and dialysis populations are the group in which carnitine kinetics have been most carefully measured Sugiyama 2021. FMO3, the enzyme that converts TMA to TMAO, and the kidney that excretes TMAO, are both variables in the same person. Anyone with reduced kidney function is a different pharmacokinetic case entirely, and that is a conversation for the clinician managing the kidney.
The fish-odor effect is real and it is the TMA pathway made visible. A minority of people, particularly those carrying reduced-function FMO3 variants, accumulate unoxidized trimethylamine and develop a body odor described as fishy. It is harmless, it is socially significant, and it is a direct readout of the same pathway the prediction block measures. Anyone who notices it on carnitine has just learned something real about their own FMO3.
What is genuinely low risk. Carnitine is a normal dietary constituent, most abundant in red meat, and gastrointestinal upset is the commonest adverse effect at gram doses Alhasaniah 2023. There is no receptor to desensitize, no withdrawal, and no dependence. The D-isomer is the exception worth naming: D-carnitine competes with the L-form at the transporter and can induce a functional deficiency, which is why the racemic mixture was withdrawn from use and why the label should say L-carnitine and nothing else.
Sources read for this page
- Chee C, et al. Increasing skeletal muscle carnitine content in older individuals increases whole-body fat oxidation during moderate-intensity exercise. Aging Cell 2021 · PMID 33464721
- Op den Kamp-Bruls YMH, et al. Carnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2025 · PMID 40019115
- Davies JS, et al. Structural basis of sodium ion-dependent carnitine transport by OCTN2. Nature Communications 2025 · PMID 41318751
- Xiang F, et al. Comprehensive review of the expanding roles of the carnitine pool in metabolic physiology: beyond fatty acid oxidation. Journal of Translational Medicine 2025 · PMID 40087749
- Rajakovich LJ, et al. Elucidation of an anaerobic pathway for metabolism of l-carnitine-derived gamma-butyrobetaine to trimethylamine in human gut bacteria. Proceedings of the National Academy of Sciences 2021 · PMID 34362844
L-Carnitine — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signaling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signaling reasoning above.
- Pregnancy — uncharacterized.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalog should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
L-Carnitine — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What L-Carnitine moves on your bloodwork
Expected direction, not a measured one.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Storage and travel
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — L-Carnitine in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside L-Carnitine
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Carnitine, Total and Free | The actual level — worth knowing before and after |
| TMAO (Trimethylamine N-oxide) | Carnitine raises TMAO, which is associated with cardiovascular risk |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The metabolic claim, measured |
| Comprehensive Metabolic Panel (CMP) | Kidney function, which governs carnitine clearance |
The Athletic Performance & Recovery panel covers these in one order — 12 markers, $207.90 with the discount applied.
Check results you already have → · All 103 markers A–Z
L-Carnitine — frequently asked questions
What is L-Carnitine?
L-Carnitine (L-Carnitine / ALCAR) is a metabolic & fat loss research compound. Shuttles long-chain fatty acids into mitochondria for oxidation — supports fat metabolism and recovery.
Is the full L-Carnitine protocol on this page?
The reported research dose is on this page, along with how L-Carnitine works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of L-Carnitine?
L-Carnitine has an approximate half-life of ~15 hrs (oral), which is part of what determines how often it's dosed.
What's the evidence behind L-Carnitine?
Current evidence level: Human (supplement). L-Carnitine is offered for research purposes only and is not an approved medicine.
L-Carnitine inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What L-Carnitine is used for
L-Carnitine appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
L-Carnitine is the direct-lipolysis arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.